Avalo Therapeutics AVTX Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's accrued manufacturing costs?
- Avalo Therapeutics (AVTX) reported accrued manufacturing costs of $1.75M in Q1 2026.
- How has Avalo Therapeutics's accrued manufacturing costs changed year-over-year?
- Avalo Therapeutics's accrued manufacturing costs decreased by 1.0% year-over-year, from $1.77M to $1.75M.
- What is the long-term trend for Avalo Therapeutics's accrued manufacturing costs?
- Over 5 years (2020 to 2025), Avalo Therapeutics's accrued manufacturing costs has grown at a 5.8% compound annual growth rate (CAGR), from $3.12M to $4.13M.